Gregory B Hammer, MD
Anesthesiology · Stanford
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Hammer’s office at (650) 723-7835 to ask if they take your plan before you enroll.
California Medical Board record
Licence G51413 · Current
Licensed to practise in California · since 1983 · expires 2027-06-30 · University of Illinois College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$4,264 in 2019
Medicaid paid $4,264 for 28 billed services this clinician did in 2019, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 28 | $4,264 |
| 2019 | 28 | 1 | 15 | $4,264 |
Money from drug and device companies
$1,125 in 2023
| 2023 | 1 | 1 | $1,125 | $1,125 |
| 2022 | 1 | 1 | $1,125 | $1,125 |
| 2021 | 3 | 5 | $7,750 | $7,900 |
| 2020 | 2 | 2 | $2,500 | $2,500 |
| 2019 | 2 | 8 | $350 | $1,777 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Edwards Lifesciences | Hemosphere | $1,125 | 1 payment
|
See the published payment
| Edwards Lifesciences | Paid to speak or teach · 2023-03-16 | Hemosphere | $1,125 |
See earlier years (2022, 2021, 2020, 2019)
2022: $1,125
| Edwards Lifesciences | Hemosphere | $1,125 | 1 payment
|
2021: $7,900
| Trevena | Olinvyk | $5,024 | 2 payments
|
| Edwards Lifesciences | Hemosphere | $2,750 | 2 payments
|
| Acacia Pharma | Byfavo | $126 | 1 payment
|
2020: $2,500
| Merck Sharp & Dohme | None | $2,000 | 1 payment
|
| Baxter Healthcare | Fluid Systems - Infusion Systems | $500 | 1 payment
|
2019: $1,777
| Merck Sharp & Dohme | Bridion | $1,427 | 7 payments
|
| Baxter Healthcare | Ips - Liquid Premix | $350 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ACACIA PHARMA INC · Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures · 2022 | Their institution | $335,810 |
| PFIZER INC. · A Phase 34 Randomized Doubleblind Doseranging Study of the Safety and Efficacy of Dexmedetomidine Dex Used With Propofol Pro As Needed for Procedural Sedation of Pediatric Subjects 1 Month To 17 Years of Age Undergoing Mri Scans · 2021 | Their institution | $207,572 |
| Merck Sharp & Dohme LLC · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2023 | Their institution | $183,957 |
| Merck Sharp & Dohme Corporation · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2021 | Their institution | $168,885 |
| Merck Sharp & Dohme Corporation · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2019 | Their institution | $153,687 |
| Hikma Pharmaceuticals USA · Morphine Pediatric Study · 2019 | Their institution | $132,733 |
| Merck Sharp & Dohme Corporation · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlledclinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616for Reversal of Neuromuscular Blockade in Pediatric Participants · 2019 | Their institution | $117,866 |
| Pacira Pharmaceuticals Incorporated · A Multicenter Study To Evaluate the Pharmacokinetics and Safety of Exparel for Postsurgical Analgesia in Pediatric Subjects Aged 6 To Less Than 17 Years. · 2019 | Their institution | $113,294 |
| Merck Sharp & Dohme Corporation · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2020 | Their institution | $107,772 |
| Merck Sharp & Dohme Corporation · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants · 2020 | Their institution | $76,224 |
| PFIZER INC. · A Phase 34 Randomized Doubleblind Doseranging Study of the Safety and Efficacy of Dexmedetomidine Dex Used With Propofol Pro As Needed for Procedural Sedation of Pediatric Subjects 1 Month To 17 Years of Age Undergoing Mri Scans · 2022 | Their institution | $39,995 |
| Masimo Corporation · Hammer Stanford Spo2 · 2019 | Their institution | $34,229 |
| Merck Sharp & Dohme LLC · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth To 2 Years · 2022 | Their institution | $28,056 |
| Pacira Pharmaceuticals Incorporated · A Multicenter Study To Evaluate the Pharmacokinetics and Safety of Exparel for Postsurgical Analgesia in Pediatric Subjects Aged 6 To Less Than 17 Years (Play) · 2020 | Their institution | $24,442 |
| Hikma Pharmaceuticals USA · Morphine Pediatric Study · 2020 | Their institution | $21,292 |
| Acacia Pharma Inc · Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures · 2021 | Their institution | $19,187 |
| PFIZER INC. · A Phase 4 Randomized Doubleblind Doseranging Study of the Efficacy Safety and Pkpd of Dexmedetomidine Dex When Used With Propofol Pro Administered As Needed for Procedural Sedation of Pediatric Subjects 1 Month To 17 Years of Age Undergoing Mri Scans · 2020 | Their institution | $17,731 |
| Masimo Corporation · Hammer / Stanford / Spo2 · 2020 | Their institution | $13,670 |
| Masimo Corporation · Hammer/Lucile Packard Children'S Hospital at Stanford/ Convenience Sample Data Collection for Invsensor00045 · 2024 | Their institution | $13,296 |
| Merck Sharp & Dohme Corporation · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex Mk-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants · 2019 | Their institution | $9,524 |
| Masimo Corporation · Convenience Sample Data Collection for Invsensor00045 · 2023 | Their institution | $8,196 |
| Trevena, Inc. · Pediatric Study · 2021 | This clinician | $4,000 |
| Masimo Corporation · Hammer Stanford Sedline Eng. Data Collection · 2019 | Their institution | $3,255 |
| PFIZER INC. · Parecoxib Sodium Clinical Publication Program · 2023 | This clinician | $3,200 |
| Masimo Corporation · Hammer/Lucile Packard Children'S Hospital at Stanford/ Convenience Sample Data Collection for Invsensor00045 · 2022 | Their institution | $2,520 |
| Merck Sharp & Dohme Corporation · A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlledclinical Trial To Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (Mk-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants · 2019 | Their institution | $1,856 |
| PFIZER INC. · Hospital Brands Clinical Publication Program · 2022 | This clinician | $330 |
| Merck Sharp & Dohme Corporation · Development and Feasibility of A Scale To Assess Postoperative Recovery the Post-Operative Quality Recovery Scale · 2020 | Their institution | $118 |
Professional record
- NPI
- 1396885455
- Licence
- CA G51413California G51413: Current · expires 2027-06-30
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G514130
- Taxonomy
- Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-07
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.